ADC Therapeutics SA Stock Forecast
NYSE: ADCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:38 AM ET
ADCT analyst consensus
Consensus (5 analysts)
none
Avg. price target
$3.33+117.60%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering ADC Therapeutics SA (2026-10-08), 3 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $3.33, with a high estimate of $5.00 and a low estimate of $2.00. The average target implies upside of 117.6% from the current price of $1.53.
The spread between the highest and lowest targets is 150.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ADCT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 60% |
| Hold | 2 | 40% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | +30.69% |
| Average target | $3.33 | +117.60% |
| High target | $5.00 | +226.73% |